Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 4;84(7):1377-1391.e6.
doi: 10.1016/j.molcel.2024.02.001. Epub 2024 Feb 28.

The proteomic landscape of genotoxic stress-induced micronuclei

Affiliations
Free article

The proteomic landscape of genotoxic stress-induced micronuclei

Kate M MacDonald et al. Mol Cell. .
Free article

Abstract

Micronuclei (MN) are induced by various genotoxic stressors and amass nuclear- and cytoplasmic-resident proteins, priming the cell for MN-driven signaling cascades. Here, we measured the proteome of micronuclear, cytoplasmic, and nuclear fractions from human cells exposed to a panel of six genotoxins, comprehensively profiling their MN protein landscape. We find that MN assemble a proteome distinct from both surrounding cytoplasm and parental nuclei, depleted of spliceosome and DNA damage repair components while enriched for a subset of the replisome. We show that the depletion of splicing machinery within transcriptionally active MN contributes to intra-MN DNA damage, a known precursor to chromothripsis. The presence of transcription machinery in MN is stress-dependent, causing a contextual induction of MN DNA damage through spliceosome deficiency. This dataset represents a unique resource detailing the global proteome of MN, guiding mechanistic studies of MN generation and MN-associated outcomes of genotoxic stress.

Keywords: DNA damage; chromothripsis; genotoxin; mass spectrometry; micronuclei; mitotic errors; proteomics; radiation; spliceosome.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.D.S. has received research funding from Takeda Pharmaceuticals and BMS and consulting fees/honorarium from Takeda, Novartis, BMS, and AstraZeneca. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada.

LinkOut - more resources